Preview

Пульмонология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Внебольничная пневмония: федеральные клинические рекомендации по диагностике и лечению

https://doi.org/10.18093/0869-0189-2022-32-3-295-355

Полный текст:

Аннотация

Внебольничная пневмония (ВП) является одним из наиболее распространенных острых инфекционных заболеваний и занимает существенную долю в структуре смертности от заболеваний органов дыхания. Крайне актуальным является подбор рациональной антибактериальной терапии, предполагающий оптимальную клиническую эффективность, улучшение прогноза, снижение скорости селекции антибиотикорезистентности и минимизацию побочных эффектов.

Методология. Целевой аудиторией данных клинических рекомендаций являются врачи-терапевты, врачи общей практики, врачи-пульмонологи, врачи-анестезиологи-реаниматологи, клинические фармакологи. Каждый тезис-рекомендация по проведению диагностических и лечебных мероприятий оценивается по шкалам уровней достоверности доказательств от 1 до 5 и шкале оценки уровней убедительности рекомендаций по категориям А, В, С. Клинические рекомендации содержат также комментарии и разъяснения к указанным тезисам-рекомендациям, алгоритмы по диагностике, тактике терапии, справочные материалы по использованию антибактериальных препаратов и проведению микробиологических (культуральных) исследований.

Заключение. По данным представленных клинических рекомендаций освещаются современные сведения об этиологии, клинических проявлениях, диагностике и тактике терапии ВП. Одобрены решением Научно-практического совета Министерства здравоохранения Российской Федерации (2021). 

Об авторах

С. Н Авдеев
Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства
Россия

д. м. н., профессор, академик Российской академии наук, заведующий кафедрой пульмонологии Института клинической медицины имени Н.В.Склифосовского, 119991, Москва, ул. Трубецкая, 8, стр. 2;

ведущий научный сотрудник, 115682, Москва, Ореховый бульвар, 28



А. В. Дехнич
Федеральное государственное бюджетное образовательное учреждение высшего образования «Смоленский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия

к. м. н., заместитель директора Научно-исследовательского института антимикробной химиотерапии,

214019, Смоленск, ул. Крупской, 28



А. А. Зайцев
Федеральное государственное бюджетное учреждение «Главный военный клинический госпиталь имени академика Н.Н.Бурденко» Министерства обороны Российской Федерации
Россия

д. м. н., профессор, главный пульмонолог,

105094, Москва, Госпитальная пл., 3



Р. С. Козлов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Смоленский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Межрегиональная ассоциация общественных объединений «Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии»
Россия

д. м. н., профессор, член-корр. Российской академии наук, ректор, 214019, Смоленск, ул. Крупской, 28;

директор, 214019, Смоленск, ул. Крупской, 28

главный внештатный специалист Министерства здравоохранения Российской Федерации
по направлению «Клиническая микробиология и антимикробная резистентность»



С. А. Рачина
Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)
Россия

д. м. н., заведующая кафедрой госпитальной терапии № 2,

119991, Москва, ул. Трубецкая, 8, стр. 2



В. А. Руднов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Государственное автономное учреждение здравоохранения Свердловской области «Свердловский областной онкологический диспансер»
Россия

д. м. н., профессор, заведующий кафедрой анестезиологии и реаниматологии, 620028 Екатеринбург, ул. Репина, 3;

руководитель службы анестезиологии и реанимации, 620036, Екатеринбург, ул. Соболева, 29

вице-президент Межрегиональной ассоциации общественных объединений «Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии»



А. И. Синопальников
Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор, заведующий кафедрой пульмонологии,

125993, Москва, ул. Баррикадная, 2 / 1, стр. 1



И. Е. Тюрин
Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор, заведующий кафедрой рентгенологии и радиологии,

125993, Москва, ул. Баррикадная, 2 / 1, стр. 1



О. В. Фесенко
Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор кафедры пульмонологии,

125993, Москва, ул. Баррикадная, 2 / 1, стр. 1



А. Г. Чучалин
Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской Федерации
Россия

д. м. н., профессор, академик Российской академии наук, заведующий кафедрой госпитальной терапии педиатрического факультета, председатель правления Российского респираторного общества,

117997, Москва, ул. Островитянова, 1



Список литературы

1. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике: пособие для врачей). Клиническая микробиология и антимикробная химиотерапия. 2010; 12 (3): 186–225. Доступно на: https://cmac-journal.ru/publication/2010/3/cmac-2010-t12-n3-p186/cmac-2010-t12-n3-p186.pdf.

2. Рачина С.А., Синопальников А.И. Инфекционные заболевания нижних дыхательных путей. В кн.: Моисеева В.С., Кобалава Ж.Д., Маева И.В. и др. (ред.) Основы внутренней медицины. М.: МИА; 2020. Т. 1: 145–205.

3. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171 (4): 388–416. DOI: 10.1164/rccm.200405-644ST.

4. Chalmers J.D., Rother C., Salih W., Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin. Infect. Dis. 2014; 58 (3): 330–339. DOI: 10.1093/cid/cit734.

5. Gross A.E.,Van Schooneveld T.C., Olsen K.M. et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob. Agents Chemother. 2014; 58 (9): 5262–5268. DOI: 10.1128/AAC.02582-14.

6. Yap V., Datta D., Metersky M.L. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect. Dis. Clin. North Am. 2013; 27 (1): 1–18. DOI: 10.1016/j.idc.2012.11.002.

7. Torres A., Blasi F., Peetermans W.E. et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur. J. Clin. Microbiol. Infect. Dis. 2014; 33 (7): 1065–1079. DOI: 10.1007/s10096-014-2067-1.

8. Johansson N., Kalin M., Tiveljung-Lindell A. et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin. Infect. Dis. 2010; 50 (2): 202–209. DOI: 10.1086/648678.

9. Рачина С.А., Козлов Р.С., Шаль Е.П. и др. Структура бактериальных возбудителей внебольничной пневмонии в многопрофильных стационарах Смоленска. Пульмонология. 2011; (1): 5–18. DOI: 10.18093/0869-0189-2011-0-1-5-18.

10. Rachina S., Zakharenkov I., Dekhnich N. et al. Aetiology of severe community-acquired pneumonia and antimic-robial resistance of Steptococcus pneumoniae in adults in Russia. J. Antimicrob. Chemother. 2021; 76 (5): 1368–1370. DOI: 10.1093/jac/dkab014.

11. Mandell L.A., Wunderink R.G, Anzueto A. et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 (Suppl. 2): S27–72. DOI: 10.1086/511159.

12. Athlin S., Lidman C., Lundqvist A. et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect. Dis. (Lond.). 2018; 50 (4): 247–272. DOI: 10.1080/23744235.2017.1399316.

13. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67 (1): 71–79. DOI: 10.1136/thx.2009.129502.

14. Климко Н.Н., Васильева Н.В. Микозы легких. В кн.: Чучалин А.Г., ред. Респираторная медицина. М.: ГЭОТАР-Медиа; 2007. Т. 1: 549–576.

15. Pavia A.T. What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia? Infect. Dis. Clin. North Am. 2013; 27 (1): 157–175. DOI: 10.1016/j.idc.2012.11.007.

16. Choi S.H., Hong S.B., Ko G.B. et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am. J. Respir. Crit. Care Med. 2012; 186 (4): 325–332. DOI: 10.1164/rccm.201112-2240OC.

17. Writing Committee of the WHO consultation on clinical aspects of pandemic (H1N1) 2009 influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 2010; 362 (18): 1708–1719. DOI: 10.1056/NEJMra1000449.

18. Bjarnason A., Westin J., Lindh M. et al. Incidence, etiology, and outcomes of community-acquired pneumonia: A population-based study. Open Forum Infect. Dis. 2018; 5 (2): ofy010. DOI: 10.1093/ofid/ofy010.

19. de Roux A., Ewig S., Garcia E. et al. Mixed community-acquired pneumonia in hospitalized patients. Eur. Respir. J. 2006; 27 (4): 795–800. DOI: 10.1183/09031936.06.00058605.

20. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Методические указания 4.2.3115-13: Методы контроля. Биологические и микробиологические факторы. Лабораторная диагностика внебольничных пневмоний. М.; 2013. Доступно на: https://docs.cntd.ru/document/1200110295.

21. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В. и др. Антибиотико-резистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014–2017». Клиническая микробиология и антимикробная химиотерапия. 2019; 21 (3): 230–237. DOI: 10.36488/cmac.2019.3.230-237.

22. Иванчик Н.В., Сухорукова М.В., Чагарян А.Н. и др. Антибиотико-резистентность клинических штаммов Haemophilus influenzae в России: результаты многоцентрового эпидемиологического исследования «ПЕГАС 2014–2017 гг.». Клиническая микробиология и антимикробная химиотерапия. 2019; 21 (4): 317–323. Доступно на: https://cmac-journal.ru/publication/2019/4/cmac-2019-t21-n4-p317/cmac-2019-t21-n4-p317.pdf.

23. Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections – summary. Clin. Microbiol. Infect. 2011; 17 (Suppl. 6): 1–59. DOI: 10.1111/j.1469-0691.2011.03602.x.

24. Козлов Р.С. Пневмококки: уроки прошлого – взгляд в будущее. Смоленск: МАКМАХ; 2010.

25. Rubinstein E., Kollef M.H., Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008; 46 (Suppl. 5): S378–S385. DOI: 10.1086/533594.

26. Faria N.A., Oliveira D.C., Westh H. et al. Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. J. Clin. Microbiol. 2005; 43 (4): 1836–1842. DOI: 10.1128/JCM.43.4.1836-1842.2005.

27. Thomas R., Ferguson J., Coombs G., Gibson P.G. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology. 2011; 16 (6): 926–931. DOI:10.1111/j.1440-1843.2011.01965.x.

28. Li H.T., Zhang T.T., Huang J. et al. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration. 2011; 81 (6): 448–460. DOI: 10.1159/000319557.

29. Gostev V., Kruglov A., Kalinogorskaya O. et al. Molecular epidemiology and antibiotic resistance of methicillin-resistant Staphylococcus aureus circulating in the Russian Federation. Infect. Genet. Evol. 2017; 53: 189–194. DOI: 10.1016/j.meegid.2017.06.006.

30. Khokhlova O.E., Hung W.C., Wan T.W. et al. Healthcare- and community-associated methicillin-resistant staphylococcus aureus (MRSA) and fatal pneumonia with pediatric deaths in Krasnoyarsk, Siberian Russia: Unique MRSA’s multiple virulence factors, genome, and stepwise evolution. PLoS One. 2015; 10 (6): e0128017. DOI: 10.1371/journal.pone.0128017.

31. Loewen K., Schreiber Y., Kirlew M. et al. Community-associated methicillin resistant Staphylococcus aureus infection: literature review and clinical update. Can. Fam. Physician. 2017; 63 (7): 512–520. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507223/

32. Edelstein I., Romanov A., Edelstein M. et al. Development and application of real-time PCR assay for detection of mutations associated with macrolide resistance in Mycoplasma pneumoniae directly in clinical specimens. Proceedings of 27th European congress of clinical microbiology and infectious diseases. April 22–25 Vienna, Austria. Vienna; 2017: 1604.

33. Sligl W.I., Marrie T.J. Severe community-acquired pneumonia. Crit. Care Clin. 2013; 29 (3): 563–601. DOI: 10.1016/j.ccc.2013.03.009.

34. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Российское респираторное общество (РРО) Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии (МАКМАХ). Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Пульмонология. 2014; (4): 13– 48. DOI: 10.18093/0869-0189-2014-0-4-13-48.

35. Gordon C.L., Holmes N.E., Grayson M.L. et al. Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection. Clin. Vaccine Immunol. 2012; 19 (3): 446–448. DOI: 10.1128/CVI.05518-11.

36. Eisen D.P., Stubbs J., Spilsbury D. et al. Low mannose-binding lectin complement activation function is associated with predisposition to Legionnaires’ disease. Clin. Exp. Immunol. 2007; 149 (1): 97–102. DOI: 10.1111/j.1365-2249.2007.03390.x.

37. Sole-Violan J., Garcia-Laorden M.I., Marcos-Ramos J.A. et al. The Fcγ receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit. Care Med. 2011; 39 (6): 1388–1393. DOI: 10.1097/CCM.0b013e31820eda74.

38. Министерство здравоохранения Российской Федерации. Заболеваемость взрослого населения России в 2019 г. М.; 2020. Часть III.

39. Jackson M.L., Neuzil K.M., Thompson W.W. et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis. 2004; 39 (11): 1642–1650. DOI: 10.1086/425615.

40. File T.M. Jr., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad. Med. 2010; 122 (2): 130–141. DOI: 10.3810/pgm.2010.03.2130.

41. Ramirez J.A., Wiemken T.L., Peyrani P. et al. Adults hospitalized with pneumonia in the united states: incidence, epidemiology, and mortality. Clin. Infect. Dis. 2017; 65 (11): 1806–1812. DOI: 10.1093/cid/cix647.

42. Федеральная служба государственной статистики. Российский статистический ежегодник. М.; 2019. Доступно на: http://www. demoscope.ru/weekly/2020/0845/biblio03.php.

43. Rodriguez A., Lisboa T., Blot S. et al. Mortality ICU patients with bacterial community acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2009; 35 (3): 430–438. DOI: 10.1007/s00134-008-1363-6.

44. Almirall J., Mesalles E., Klamburg J. et al. Prognostic factors of pneumonia reqiring admission to the intensive care unit. Chest. 1995; 107 (2): 511–516. DOI: 10.1378/chest.107.2.511.

45. Fine M.J., Smith M.A., Carson C.A. et al. Prognosis and outcome of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996; 275 (2): 134–141. DOI: 10.1001/jama.1996.03530260048030.

46. Трифанова Н.М., Лещенко И.В. Факторы риска летального исхода при тяжелой внебольничной пневмонии. Уральский медицинский журнал. 2008; (13 (53)): 114–121.

47. Шаймуратов Р.И. Структурный анализ причин летальных исходов пациентов, госпитализированных с внебольничной пневмонией в стационары Татарстана: Дисс. … канд. мед. наук. Санкт-Петербург; 2018.

48. Müller B., Harbarth S., Stolz D. et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.BMC Infect. Dis. 2007; 7: 10. DOI: 10.1186/1471-2334-7-10.

49. Zalacain R., Torres A., Celis R. et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur. J. Respir. 2003; 21 (2): 294–302. DOI: 10.1183/09031936.03.00064102.

50. Kaplan V., Angus D.C. Community-acquired pneumonia in the elderly. Crit. Care Clin. 2003; 19 (4): 729–748. DOI: 10.1016/s0749-0704(03)00057-5.

51. Синопальников А.И., Фесенко О.В. Внебольничная пневмония у взрослых. В кн.: Чучалин А.Г., ред. Респираторная медицина. 2-е изд. М.: ГЭОТАР-Медиа; 2017. Т. 2: 29–67.

52. Bewick T., Greenwood S., Lim W.S. What is the role of pulse oximetry in the assessment of patients with community-acquired pneumonia in primary care? Prim. Care Respir. J. 2010; 19 (4): 378–382. DOI: 10.4104/pcrj.2010.00049.

53. de Jager C.P.C., Wever P.C., Gemen E.F.A. et al. The neutrophil-lymphocyte count ratio in patients with community-acquired pneumonia. PLoS One. 2012; 7 (10): e46561. DOI: 10.1371/journal.pone.0046561.

54. Tamayose M., Fujita J., Parrott G. et al. Correlations between extent of X-ray infiltration and levels of serum C-reactive protein in adult non-severe community-acquired pneumonia. J. Infect. Chemother. 2015; 21 (6): 456–463. DOI: 10.1016/j.jiac.2015.02.009.

55. Ebell M.H., Bentivegna M., Cai X. et al. Accuracy of biomarkers for the diagnosis of adult community-acquired pneumonia: a metaanalysis. Acad. Emerg. Med. 2020; 27 (3): 195–206. DOI: 10.1111/acem.13889.

56. Schuetz P., Litke A., Albrich W.C., Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr. Opin. Infect. Dis. 2013; 26 (2): 159–167. DOI: 10.1097/QCO.0b013e32835d0bec.

57. Bruns A.H., Oosterheert J.J., Hak E., Hoepelman A.I. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur. Respir. J. 2008; 32: 726–732. DOI: 10.1183/09031936.00003608.

58. Nouvenne A., Ticinesi A., Folesani G. et al. The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study. BMC Geriatr. 2016; 16: 16. DOI: 10.1186/s12877-016-0192-7.

59. Chalmers J.D., Singanayagam A., Hill A.T. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am. J. Med. 2008; 121 (3): 219–225. DOI: 10.1016/j.amjmed.2007.10.033.

60. Nseir W., Farah R., Mograbi J., Makhoul N. Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: a cohort study. J. Crit. Care. 2013; 28 (3): 291–295. DOI: 10.1016/j.jcrc.2012.09.012.

61. Liu D., Su L.X., Guan W. et al. Prognostic value of procalcitonin in pneumonia: a systematic review and meta-analysis. Respirology. 2016; 21 (2): 280–288. DOI: 10.1111/resp.12704

62. Hedlund J., Hansson L.O. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection. 2000; 28 (2): 68–73. DOI: 10.1007/s150100050049.

63. Johansson N., Kalin M., Backman-Johansson C. et al. Procalcitonin levels in community-acquired pneumonia – correlation with aetiology and severity. Scand. J. Infect. Dis. 2014; 46 (11): 787–791. DOI: 10.3109/00365548.2014.945955.

64. de Jong E., van Oers J. A., Beishuizen A. et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically Ill patients: a randomised, controlled, open-label trial. Lancet Infect. Dis. 2016; 16 (7): 819–827. DOI: 10.1016/S1473-3099(16)00053-0.

65. Menendez R., Martinez R., Reyes S. et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009; 64 (7): 587–591. DOI: 10.1136/thx.2008.105312.

66. Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 2013; 41 (2): 580–637. DOI: 10.1097/ccm.0b013e31827e83af.

67. Hökenek N.M., Seyhan A.U., Erdogan M.O. et al. Evaluation of blood gas analysis as a mortality predictor. South Clin. Ist. Euras. 2019; 30 (3): 228–231. DOI: 10.14744/scie.2019.44365.

68. Howell M.D., Donnino M., Clardy P. et al. Occult hypoperfusion and mortality in patients with suspected infection. Intensive Care Med. 2007; 33 (11): 1892–1899. DOI: 10.1007/s00134-007-0680-5.

69. Zhou H., Lan T., Guo S. Prognostic prediction value of qSOFA, SOFA, and admission lactate in septic patients with community-acquired pneumonia in emergency department. Emerg. Med. Int. 2020: 7979353. DOI: 10.1155/2020/7979353.

70. Wiersinga W.J., BontenM.J., Boersma W.G. et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch working party on antibiotic policy (SWAB) and Dutch association of chest physicians (NVALT). Neth. J. Med. 2018; 76 (1): 1–13. Available at: https://www.njmonline.nl/article.php?a=1933&d=1280&i=212

71. Рачина С.А., Иванчик Н.В., Козлов Р.С. Особенности микробиологической диагностики при внебольничной пневмонии у взрослых. Практическая пульмонология. 2016; (4): 40–47. Доступно на: http://www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_4_2016_40.pdf.

72. Рачина С.А., Сухорукова М.В. Микробиологическая диагностика инфекций нижних дыхательных путей. В кн.: Моисеева В.С., Кобалава Ж.Д., Маева И.В. и др. (ред.). Основы внутренней медицины. 2-е изд. М.: МИА; 2020; Т. 1:97–106.

73. O’Horo J. C., Thompson D., Safdar N. Is the gram stain useful in the microbiologic diagnosis of VAP? A meta-analysis. Clin. Infect. Dis. 2012; 55 (4): 551–561. DOI: 10.1093/cid/cis512.

74. Garcia L.S., Isenberg H.D., eds. Clinical microbiology procedures handbook. 3rd edn. Washington, DC: ASM Press; 2010.

75. Walden A.P., Clarke G.M., McKechnie S. et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit. Care. 2014; 18 (2): R58. DOI: 10.1186/cc13812.

76. Campbell S.G., Marrie T.J., Anstey R. et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest. 2003; 123 (4): 1142–1150. DOI: 10.1378/chest.123.4.1142.

77. Waterer G.W., Wunderink R.G. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir. Med. 2001; 95 (1): 78–82. DOI: 10.1053/rmed.2000.0977.

78. Metersky M.L., Ma A., Bratzler D.W. et al. Predicting bacteremia in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2004; 169 (3): 342-347. https://doi.org/10.1164/rccm.200309-1248OC

79. Dunn J.J., Ginocchio C.C. Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of influenza virus infections? J. Clin. Microbiol. 2015; 53 (6): 1790–1796. DOI: 10.1128/JCM.02739-14.

80. Chow E.J., Doyle J.D., Uyeki T.M. Influenza virus-related critical Illness: prevention, diagnosis, treatment. Crit. Care. 2019; 23 (1): 214. DOI: 10.1186/s13054-019-2491-9.

81. Kashuba A.D., Ballow C.H. Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn. Microbiol. Infect. Dis. 1996; 24 (3): 129–139. DOI: 10.1016/0732-8893(96)00010-7.

82. Blazquez R.M., Espinosa F.J., Martinez-Toldos C.M. et al. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 2005; 24 (7): 488–491. DOI: 10.1007/s10096-005-1361-3.

83. Чучалин А.Г., Синопальников А.И., Тартаковский И.С. и др. Практические рекомендации по диагностике и лечению легионеллезной инфекции, вызванной Legionella pneumophila серогруппы 1: пособие для врачей. М.; 2009.

84. Тартаковский И.С. Диагностика и профилактика легионеллеза. Поликлиника. 2015; (6): 40–43. Доступно на: http://www.poliklin.ru/imagearticle/201502(1)_LAB/40-43.pdf.

85. Harris A.M., Beekmann S.E., Polgreen P.M. et al. Rapid urine antigen testing for Streptococcus pneumoniae in adults with community-acquired pneumonia: clinical use and barriers. Diagn. Microbiol. Infect. Dis. 2014; 79 (4): 454–457. DOI: 10.1016/j.diagmicrobio.2014.05.008.

86. Sinclair A., Xie X., Teltscher M., Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J. Clin. Microbiol. 2013; 51 (7): 2303–2310. DOI: 10.1128/JCM.00137-13.

87. Horita N., Miyazawa N., Kojima R. et al. Sensitivity and specificity of the Streptococcus pneumoniae urinary antigen test for unconcentrated urine from adult patients with pneumonia: a meta-analysis. Respirology. 2013; 18 (8): 1177–1183. DOI: 10.1111/resp.12163.

88. Costantini E., Allara E., Patrucco F. et al. Adherence to guidelines for hospitalized community-acquired pneumonia over time and Its impact on health outcomes and mortality. Intern. Emerg. Med. 2016; 11 (7): 929–940. DOI: 10.1007/s11739-016-1445-3.

89. Piso R.J., Iven-Koller D., Koller M.T. et al. The routine use of urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment. Swiss Med. Wkly. 2012; 142: w13679. DOI: 10.4414/smw.2012.13679.

90. Meduri G.U., Baselski V. The role of bronchoalveolar lavage in diagnosing nonopportunistic bacterial pneumonia. Chest. 1991; 100 (1): 179–190. DOI: 10.1378/chest.100.1.179.

91. Pereira Gomes J.C., Pedreira W.L. Jr, Araujo E.M. et al. Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy. Chest. 2000; 118 (6): 1739–1746. DOI: 10.1378/chest.118.6.1739.

92. Lim W.S., Baudouin S.V., George R.C. et al. BTS guidelines for the management of community-acquired pneumonia in adults – update 2009. Thorax. 2009; 64 (Suppl. 3): iii1–55. DOI: 10.1136/thx.2009.121434.

93. Ebell M. H., Chupp H., Cai X. et al. Accuracy of signs and symptoms for the diagnosis of community-acquired pneumonia: a metaanalysis. Acad. Emerg. Med. 2020; 27 (7): 541–553. DOI: 10.1111/acem.13965.

94. Тюрин И.Е. Методы визуализации. В кн.: Чучалин А.Г., ред. Респираторная медицина. 2-е изд. М.: ГЭОТАР-Медиа; 2017. Т. 1: 245–302. / Tyurin I.E. [Imaging methods]. In: Chuchalin A.G., ed. [Respiratory Medicine]. 2nd edn. Moscow: GEOTAR-Media; 2017. Vol. 1: 245–302 (in Russian).

95. Hayden G.E., Wrenn K.W. Chest radiograph vs. computed tomography scan in the evaluation for pneumonia. J. Emerg. Med. 2009; 36 (3): 266–270. DOI: 10.1016/j.jemermed.2007.11.042.

96. Self W.H., Courtney D.M., McNaughton C.D. et al. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. Am. J. Emerg. Med. 2013; 31 (2): 401–405. DOI: 10.1016/j.ajem.2012.08.041.

97. Claessens Y.E., Debray M.P., Tubach F. et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2015; 192 (8): 974–982. DOI: 10.1164/rccm.201501-0017OC.

98. Franquet T. Imaging of pneumonia: trends and algorithms. Eur. Respir. J. 2001; 18 (1): 196–208. DOI: 10.1183/09031936.01.00213501.

99. Corrales-Medina V.F., Suh K.N., Rose G. et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011; 8 (6): e1001048. DOI: 10.1371/journal.pmed.1001048.

100. Ye X., Xiao H., Chen B. et al. Accuracy of lung ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: review of the literature and meta-analysis. PLoS One. 2015; 10 (6): e0130066. DOI: 10.1371/journal.pone.0130066.

101. Фесенко О.В., Синопальников А.И. Заболевания плевры. В кн.: Моисеева В.С., Кобалава Ж.Д., Маева И.В. и др. (ред.) Основы внутренней медицины. М.: МИА; 2020. Т. 2: 265–272.

102. Chavez M.A., Shams N., Ellington L.E. et al. Lung ultrasound for the diagnosis of pneumonia in adults: a systematic review and meta-analysis. Respir. Res. 2014; 15 (1): 50. DOI: 10.1186/1465-9921-15-50.

103. Lichtenstein D.A. BLUE-Protocol and FALLS-Protocol: two applications of lung ultrasound in the critically ill. Chest. 2015; 147 (6): 1659–1670. DOI: 10.1378/chest.14-1313.

104. Llamas-Álvarez A.M., Tenza-Lozano E.M., Latour-Pérez J. et al. Accuracy of lung ultrasono-graphy in the diagnosis of pneumonia in adults: systematic review and meta-analysis. Chest. 2017; 151 (2): 374–382. DOI: 10.1016/j.chest.2016.10.039.

105. Battleman D.S., Callahan M., Thaler H.T. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch. Intern. Med. 2002; 162 (6): 682–688. DOI: 10.1001/archinte.162.6.682.

106. Houck P.M., Bratzler D.W., Nsa W. et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 2004; 164 (6): 637–644. DOI: 10.1001/archinte.164.6.637.

107. Mortensen E.M., Restrepo M., Anzueto A. et al. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am. J. Med. 2004. 117 (10): 726–731. DOI: 10.1016/j.amjmed.2004.06.028.

108. Menendez R., Ferrando D., Valles J.M., Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest. 2002; 122: 612–617. DOI: 10.1378/chest.122.2.612.

109. Dean N.C., Silver M.P., Bateman K.A. et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am. J. Med. 2001; 110 (6): 451–457. DOI: 10.1016/s0002-9343(00)00744-0.

110. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect. 2020; 81 (2): 266–275. DOI: 10.1016/j.jinf.2020.05.046.

111. Pakhale S., Mulpuru S., Verheij T.J.M. et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst. Rev. 2014; (10): CD002109. DOI: 10.1002/14651858.CD002109.pub4.

112. Fredlund H., Bodin L., Back E. et al. Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin. Scand. J. Infect. Dis. 1987; 19 (4): 459–466. DOI: 10.3109/00365548709021679.

113. Lode H., File T.M., Mandell L. et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. 2002; 24 (11): 1915–1936. DOI: 10.1016/s0149-2918(02)80088-1.

114. Zuck P., Rio Y., Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J. Antimicrob. Chemother. 1990; 26 (Suppl. E): 71–77. DOI: 10.1093/jac/26.suppl_e.71.

115. Maimon N., Nopmaneejumruslers C., Marras T.K. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur. Respir. J. 2008; 31 (5): 1068–1076. DOI: 10.1183/09031936.00109007.

116. Boyles T.H., Brink A., Calligaro G.L. et al. South African guideline for the management of community- acquired pneumonia in adults. J. Thorac. Dis. 2017; 9 (6): 1469–1502. DOI: 10.21037/jtd.2017.05.31.

117. Metlay J.P., Watere G.W., Long A.C. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med. 2019; 200 (7): e45–67. DOI: 10.1164/rccm.201908-1581ST.

118. Lonks J.R., Garau J., Gomez L. et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 2002; 35 (5): 556–564. DOI: 10.1086/341978.

119. Daneman N., McGeer A., Green K. et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin. Infect. Dis. 2006; 43 (4): 432–438. DOI: 10.1086/505871.

120. Niederman M.S. In the clinic: community-acquired pneumonia. Ann. Intern. Med. 2015; 163 (7): 1–17. DOI: 10.7326/AITC201510060.

121. Козлов Р.С., Рачина С.А., Захаренко С.М. Общие принципы антимкробной химиотерапии инфекционных больных. В кн.: Лобзин Ю.В., Жданов К.В., ред. Руководство по инфекционным болезням. 4-е изд. Санкт-Петербург: Фолиант, 2011: 58–106.

122. Dimopoulos G., Matthaiou D.K., Karageorgopoulos D.E. et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008; 68 (13): 1841– 1854. DOI: 10.2165/00003495-200868130-00004.

123. el Moussaoui R., de Borgie C.A.J.M., van den Broek P. et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006; 332 (7554): 1355. DOI: 10.1136/bmj.332.7554.1355.

124. Dunbar L.M., Wunderink R.G., Habib M.P. et al. High-dose, shortcourse levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis.2003; 37 (6): 752–760. DOI: 10.1086/377539.

125. Sligl W.I., Asadi L., Eurich D.T. et al. Macrolides and mortality in critically Ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit. Care Med. 2014; 42 (2): 420–432. DOI: 10.1097/CCM.0b013e3182a66b9b.

126. Daniel P., Rodrigo C., Mckeever T.M. et al. Time to first antibiotic and mortality in adults hospitalised with community-acquired pneumonia: a matched-propensity analysis. Thorax. 2016; 71 (6): 568–570. DOI: 10.1136/thoraxjnl-2015-207513.

127. Liu V.X., Fielding-Singh V., Greene J.D. et al. The timing of early antibiotics and hospital mortality in sepsis. Am. J. Respir. Crit. Care Med. 2017; 196 (7): 856–863. DOI: 10.1164/rccm.201609-1848OC.

128. Marras T.K., Nopmaneejumruslers C., Chan C.K.N. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. Am. J. Med. 2004; 116 (6): 385–393. DOI: 10.1016/j.amjmed.2003.11.013.

129. Paul M., Dickstein Y., Raz-Pasteur A. Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis. Clin. Microbiol. Infect. 2016; 22 (12): 960–967. DOI: 10.1016/j.cmi.2016.05.023.

130. Postma D.F., van Werkhoven C.H., van Elden L.J. et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N. Engl. J. Med. 2015; 372 (14): 1312–1323. DOI: 10.1056/NEJMoa1406330.

131. Garin N., Genne D., Carballo S. et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern. Med.2014; 174 (12): 1894–1901. DOI: 10.1001/jamainternmed.2014.4887.

132. Carreno J.J., Lodise TP. Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE. Infect. Dis. Ther. 2014; 3 (2): 123–132. DOI: 10.1007/s40121-014-0036-8.

133. Grau S., Lozano V., Valladares A. et al. Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain. Clinicoecon. Outcomes Res. 2014; 6: 83–92. DOI: 10.2147/CEOR.S55265.

134. Rodríguez A., Mendia A., Sirvent J.M. et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit. Care Med. 2007; 35 (6): 1493–1498. DOI: 10.1097/01.CCM.0000266755.75844.05.

135. Horita N., Otsuka T, Haranaga S. et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology. 2016; 21 (7): 1193–1200. DOI: 10.1111/resp.12835.

136. Lee J.H., Kim H.J., Kim Y.H. Is β-Lactam plus macrolide more effective than β-Lactam plus fluoroquinolone among patients with severe community-acquired pneumonia? A systemic review and meta-analysis. J. Korean. Med. Sci. 2017; 32 (1): 77–84. DOI: 10.3346/jkms.2017.32.1.77.

137. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 2001; 161 (15): 1837–1842. DOI: 10.1001/archinte.161.15.1837.

138. Martínez J.A., Horcajada J.P., Almela M. et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 2003; 36 (4): 389–395. DOI: 10.1086/367541.

139. Baddour L.M., Yu V.L., Klugman K.P. et al. Combination antibiotic therapy lowers mortality among severely ill patients with Pneumococcal bacteraemia. Am. J. Respir. Crit. Care Med. 2004; 170 (4): 440–444. DOI: 10.1164/rccm.200311-1578OC.

140. Gattarello S., Borgatta B., Solé-Violán J. et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013). Chest. 2014; 146 (1): 22–31. DOI: 10.1378/chest.13-1531.

141. De la Calle C., Ternavasio-de la Vega H.G., Morata L. et al. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J. Infection. 2018; 76 (4): 342–347. DOI: 10.1016/j.jinf.2018.01.003.

142. Gattarello S., Lagunes L., Vidaur L. et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit. Care. 2015; 19 (1): 335. DOI: 10.1186/s13054-015-1051-1.

143. Torres A., Garau J., Arvis P. et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin. Infect. Dis. 2008; 46 (10): 1499–1509. DOI: 10.1086/587519.

144. Leroy O., Saux P., Bédos J.P., Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest. 2005; 128 (1): 172–183. DOI: 10.1378/chest.128.1.172.

145. Paul M., Dickstein Y., Raz-Pasteur A. Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis. Clin. Microbiol. Infect. 2016; 22 (12): 960–967. DOI: 10.1016/j.cmi.2016.05.023.

146. Garnacho-Montero J., Barrero-García I., Gómez-Prieto M.G. et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev. Anti Infect. Ther. 2018; 16 (9): 667–677. DOI: 10.1080/14787210.2018.1512403.

147. Martin-Loeches I., Lisboa T., Rodriguez A. et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010; 36 (4): 612–620. DOI: 10.1007/s00134-009-1730-y.

148. Restrepo M.I., Mortensen E.M., Waterer G.W. et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J. 2009; 33 (1): 153–159. DOI: 10.1183/09031936.00054108.

149. Козлов Р.С., Дехнича А.В., ред. Справочник по антимикробной химиотерапии. Смоленск: МАКМАХ; 2013. Вып. 3. / Kozlov R.S., Dekhnicha A.V., eds. [Handbook of antimicrobial chemotherapy]. Smolensk: IACMAC; 2013. Issue 3 (in Russian).

150. Shorr A.F., Kollef M., Eckburg P.B. et al. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to streptococcus pneumoniae: insights from two randomized trials. Diagn. Microbiol. Infect. Dis. 2013; 75 (3): 298–303. DOI: 10.1016/j.diagmicrobio.2012.12.002.

151. Cristinacce A., Wright J.G., Stone G.G. et al. A retrospective analysis of probability of target attainment in community-acquired pneumonia: ceftaroline fosamil versus comparators. Infect. Dis. Ther. 2019; 8 (2): 185–198. DOI: 10.1007/s40121-019-0243-4.

152. Ollivier J., Carrie C., d’Houdain N. et al. Are standard dosing regimens of ceftriaxone adapted for critically Ill patients with augmented creatinine clearance? Antimicrob Agents Chemother. 2019; 63 (3): e02134–02218. DOI: 10.1128/AAC.02134-18.

153. Рачина С.А., Козлов Р.С., Дехнич Н.Н. и др. Антибактериальная терапия тяжелой внебольничной пневмонии у взрослых: обзор рекомендаций и клинические примеры. Архив внутренней медицины. 2015; 23 (3): 63–74. DOI: 10.20514/2226-6704-2015-0-3-63-74.

154. Restrepo M.I., Babu B.L., Reyes L.F. et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur. Respir. J. 2018; 52 (2): 1701190. DOI: 10.1183/13993003.01190-2017.

155. Shindo Y., Sato S., Maruyama E. et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009; 135 (3): 633–640. DOI: 10.1378/chest.08-1357.

156. Prina E., Ranzani O.T., Polverino E. et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann. Am. Thorac Soc. 2015; 12 (2): 153–160. DOI: 10.1513/AnnalsATS.201407-305OC.

157. González-Castillo J., Martín-Sánchez F.J., Llinares P. et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev. Esp. Quimioter. 2014; 27 (1): 69–86. Available at: https://seq.es/seq/0214-3429/27/1/gonzalez.pdf

158. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Антибактериальная терапия инфекций нижних дыхательных путей. В кн.: Страчунский Л.С., Козлов С.Н., Белоусов Ю.Б., ред. Практическое руководство по антиинфекционной химиотерапии. Смоленск: МАКМАХ; 2007: 258–266.

159. von Baum H., Welte T., Marre R. et al. Community-acquired pneumonia through enterobacteriaceae and pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur. Respir. J. 2010; 35 (3): 598–605. DOI: 10.1183/09031936.00091809.

160. Calbo E., Romaní V., Xercavins M. et al. Risk factors for communityonset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 2006; 57 (4): 780–783. DOI: 10.1093/jac/dkl035.

161. Rodríguez-Baño J., Navarro M.D., Romero L. et al. Epidemiology and clinical fea- tures of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in non hospitalized patients. J. Clin. Microbiol. 2004; 42 (3): 1089–1094. DOI: 10.1128/JCM.42.3.1089-1094.2004.

162. Marik P.E. Aspiration pneumonitis and aspiration pneumonia. N. Engl. J. Med. 2001; 344 (9): 665–671. DOI: 10.1056/NEJM200103013440908.

163. Marrie T.J., Durant H., Kwan C. Nursing home-acquired pneumonia. A case-control study. J. Am. Geriatr. Soc. 1986; 34 (10): 697–702. DOI: 10.1111/j.1532-5415.1986.tb04300.x.

164. Cesar L., Gonzalez C., Calia F.M. Bacteriologic flora of aspiration-induced pulmonary infections. Arch. Intern. Med. 1975; 135 (5): 711–714. DOI: 10.1001/archinte.135.5.711.

165. El-Solh A.A., Pietrantoni C., Bhat A. et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am. J. Respir. Crit. Care Med. 2003; 167 (12): 1650–1654. DOI: 10.1164/rccm.200212-1543OC.

166. Marik P.E., Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest. 1999; 115 (1): 178–183. DOI: 10.1378/chest.115.1.178.

167. Mier L., Dreyfuss D., Darchy B. et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med. 1993; 19 (5): 279–284. DOI: 10.1007/BF01690548.

168. Dobson J., Whitley R.J., Pocock S. et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015; 385 (9979): 1729–1737. DOI: 10.1016/S0140-6736(14)62449-1.

169. Louie J.K., Yang S., Acosta M. et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1) pdm09. Clin. Infect. Dis. 2012; 55 (9): 1198–1204. DOI: 10.1093/cid/cis636.

170. Heneghan C.J., Onakpoya I., Jones M.A. et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol. Assess. 2016; 20 (42): 1–242. DOI: 10.3310/hta20420.

171. Lee N., Choi K.W., Chan P.K.S. et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010; 65 (6): 510–515. DOI: 10.1136/thx.2009.130799.

172. McGeer A., Green K.A., Plevneshi A. et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 2007; 45 (12): 1568–1575. DOI: 10.1086/523584.

173. Morel J., Casoetto J., Jospe R. et al. De-escalation as part of a global strategy of empiric antibiotherapy management: a retrospective study in a medico-surgical intensive care unit. Crit. Care. 2010; 14 (6): R225. DOI: 10.1186/cc9373.

174. Leone M., Bechis C., Baumstarck K. et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014; 40 (10): 1399–1408. DOI: 10.1007/s00134-014-3411-8.

175. Gutierrez-Pizarraya A., Leone M., Garnacho-Montero J. et al. Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis. Expert Rev. Clin. Pharmacol. 2017; 10 (4): 457–465. DOI: 10.1080/17512433.2017.1293520.

176. Rhew D.C., Tu G.S., Ofman J. et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch. Intern. Med. 2001; 161 (5): 722–727. DOI: 10.1001/archinte.161.5.722.

177. Halm E.A., Fine M.J., Marrie T.J. et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998; 279 (18): 1452–1457. DOI: 10.1001/jama.279.18.1452.

178. Ramirez J.A., Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch. Intern. Med. 2001; 161 (6): 848–850. DOI: 10.1001/archinte.161.6.848.

179. Tansarli G.S., Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for communityacquired pneumonia in adults. Antimicrob Agents Chemother. 2018; 62 (9): e00635–00718. DOI: 10.1128/AAC.00635-18.

180. Tejerina E., Frutos-Vivar F., Restrepo M.I. et al. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J. Crit. Care. 2005; 20 (3): 230–238. DOI: 10.1016/j.jcrc.2005.05.010.

181. Mortensen E.M., Coley C.M., Singer D.E. et al. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team cohort study. Arch. Intern. Med. 2002; 162 (9): 1059–1064. DOI: 10.1001/archinte.162.9.1059.

182. Pascual F.E., Matthay M.A., Bacchetti P., Pascual F.E. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest. 2000; 117 (2): 503–512. DOI: 10.1378/chest.117.2.503.

183. Barrot L., Asfar P., Mauny F. et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. N. Engl. J. Med. 2020; 382 (11): 999–1008. DOI: 10.1056/NEJMoa1916431.

184. Авдеев С.Н. Ургентная кислородотерапия. Вестник анестезиологии и реаниматологии. 2011; (3): 42–51. Доступно на: https://cyberleninka.ru/article/n/urgentnaya-kislorodoterapiya-pri-dyhatelnoy-nedostatochnosti/viewer.

185. Barcroft J., Camis M. The dissociation curve of blood. J. Physiol. 1909; 39 (2): 118–142. DOI: 10.1113/jphysiol.1909.sp001330.

186. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 2000; 342 (18): 1301–1308. DOI: 10.1056/NEJM200005043421801.

187. Ярошецкий А.И., Власенко А.В., Грицан А.И. и др. Применение неинвазивной вентиляции легких (второй пересмотр). Клинические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Анестезиология и реаниматология. 2019; (6): 5–19. DOI: 10.17116/anaesthesiology20190615.

188. Mauri T., Turrini C., Eronia N. et al. Physiologic effects of highflow nasal cannula in acute hypoxemic respiratory failure. Am. J. Respir. Crit. Care Med. 2017; 195 (9): 1207–1215. DOI: 10.1164/rccm.201605-0916OC.

189. Frat J.P., Thille A.W.,Mercat A. et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N. Engl. J. Med. 2015; 372 (23): 2185–2196. DOI: 10.1056/NEJMoa1503326.

190. Grieco D.L., Menga L.S., Raggi V. et al. Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure. Am. J. Respir. Crit. Care Med. 2020; 201 (3): 303–312. DOI: 10.1164/rccm.201904-0841OC.

191. Ferreyro B.L., Angriman F., Munshi L. et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. JAMA. 2020; 324 (1): 57–67. DOI: 10.1001/jama.2020.9524.

192. Carteaux G., Millán-Guilarte T., De Prost N. et al. Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume. Crit. Care Med. 2016; 44 (2): 282–290. DOI: 10.1097/CCM.0000000000001379.

193. Frat J.P., Ragot S., Coudroy R. et al. Predictors of Intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy. Crit. Care Med. 2018; 46 (2): 208–215. DOI: 10.1097/CCM.0000000000002818.

194. Hraiech S., Alingrin J., Dizier S. et al. Time to intubation is associated with outcome in patients with community-acquired pneumonia. PLoS One. 2013; 8 (9): e74937. DOI: 10.1371/journal.pone.0074937.

195. Kangelaris K.N., Ware L.B., Wang C.Y. et al. Timing of intubation and clinical outcomes in adults with acute respiratory distress syndrome. Crit. Care Med. 2016; 44 (1): 120–129. DOI: 10.1097/CCM.0000000000001359.

196. Kang B.J., Koh Y., Lim C.M. et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015; 41 (4): 623–632. DOI: 10.1007/s00134-015-3693-5.

197. Brochard L., Lefebvre J.C., Cordioli R.L. et al. Noninvasive ventilation for patients with hypoxemic acute respiratory failure. Semin. Respir. Crit. Care Med. 2014; 35 (4): 492–500. DOI: 10.1055/s-0034-1383863.

198. Confalonieri M., Potena A., Carbone G. et al. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation. Am. J. Respir. Crit. Care Med. 1999; 160 (5, Pt 1): 1585–1591. DOI: 10.1164/ajrccm.160.5.9903015.

199. Jolliet P., Abajo B., Pasquina P., Chevrolet J.C. Non-invasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med. 2001; 27 (5): 812–821. DOI: 10.1007/s001340100869.

200. Domenighetti G., Gayer R., Gentilini R. Noninvasive pressure support ventilation in non-COPD patients with acute cardiogenic pulmonary edema and severe community-acquired pneumonia: acute effects and outcome. Intensive Care Med. 2001; 28 (9): 1226–1232. DOI: 10.1007/s00134-002-1373-8.

201. Ferrer M., Esquinas A., Leon M. et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am. J. Respir. Crit. Care Med. 2003; 168 (12): 1438–1444. DOI: 10.1164/rccm.200301-072OC.

202. Kohno S., Seki M., Takehara K. et al. Prediction of requirement for mechanical ventilation in community-acquired pneumonia with acute respiratory failure: a multicenter prospective study. Respiration. 2013; 85 (1): 27–35. DOI: 10.1159/000335466.

203. Brochard L., Slutsky A., Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am. J. Respir. Crit. Care Med. 2017; 195 (4): 438–442. DOI: 10.1164/rccm.201605-1081CP.

204. Tonelli R., Fantini R., Tabbì L. et al. Inspiratory effort assessment by esophageal manometry early predicts noninvasive ventilation outcome in de novo respiratory failure: a pilot study. Am. J. Respir. Crit. Care Med. 2020; 202 (4): 558–567. DOI: 10.1164/rccm.201912-2512OC.

205. Demoule A., Jung B., Prodanovic H. et al. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact – a prospective study. Am. J. Respir. Crit. Care Med. 2013; 188 (2): 213–219. DOI: 10.1164/rccm.201209-1668OC.

206. Behazin N., Jones S.B., Cohen R.I., Loring S.H. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. J. Appl. Physiol. 2010; 108 (1): 212–218. DOI: 10.1152/japplphysiol.91356.2008.

207. Tobin M.J. Basing respiratory management of coronaviruson physiological principles. Am. J. Respir. Crit. Care Med. 2020; 201 (11): 1319–1320. DOI: 10.1164/rccm.202004-1076ED.

208. Yaroshetskiy A.I., Avdeev S.N., Konanykhin V.D. Acute respiratory distress syndrome in COVID-19: Do all these patients definitely require intubation and mechanical ventilation? Am. J. Respir. Crit. Care Med. 2020; 202 (10): 1480–1481 DOI: 10.1164/rccm.202007-2713LE.

209. Guerin C., Reignier J., Richard J.C. et al. Prone positioning in severe acute respiratory distress syndrome. N. Engl. J. Med. 2013; 368 (23): 2159–2168. DOI: 10.1056/NEJMoa1214103.

210. Munshi L., Del Sorbo L., Adhikari N.K.J. et al. Prone position for acute respiratory distress syndrome: a systematic review and meta-analysis. Ann. Am. Thorac. Soc. 2017; 14 (Suppl. 4): S280–288. DOI: 10.1513/AnnalsATS.201704-343OT.

211. Dreyfuss D., Djedaini K., Lanore J.J. et al. A comparative study of the effects of almitrine bismesylate and lateral position during unilateral bacterial pneumonia with severe hypoxemia. Am. Rev. Respir. Dis. 1992; 146 (2): 295–299. DOI:10.1164/ajrccm/146.2.295.

212. Rouby J.J., Lu Q., Goldstein I. Selecting the right level of positive end-expiratory pressure in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2002; 165 (8): 1182–1186. DOI: 10.1164/ajrccm.165.8.2105122.

213. Albaiceta G.M., Taboada F., Parra D. et al. Differences in the deflation limb of the pressure-volume curves in acute respiratory distress syndrome from pulmonary and extrapulmonary origin. Intensive Care Med. 2003; 29 (11): 1943–1949. DOI: 10.1007/s00134-003-1965-y.

214. Ярошецкий А.И., Проценко Д.Н., Бойцов П.В. и др. Оптимальное положительное конечно-экспираторное давление при ОРДС у больных с гриппом А(H1N1)pdm09: баланс между максимумом конечно-экспираторного объема и минимумом перераздувания альвеол. Анестезиология и реаниматология. 2016; 61 (6): 425–432. Доступно на: https://cyberleninka.ru/article/n/optimalnoe-polozhitelnoe-konechno-ekspiratornoe-davlenie-pri-ords-u-bolnyh-grippom-a-h1n1-pdm09-balans-mezhdu-maksimumom-konechno

215. Amato M.B.P., Meade M.O., Slutsky A.S. et al. Driving pressure and survival in the acute respiratory distress syndrome. N. Engl. J. Med.2015; 372 (8): 747–755. DOI: 10.1056/NEJMsa1410639.

216. Dessap A.M., Boissier F., Charron C. et al. Acute cor pulmonale during protective ventilation: prevalence, predictors and clinical impact. Intensive Care Med. 2016; 42 (5): 862–870. DOI: 10.1007/s00134-015-4141-2.

217. Mendes P.V., Melro L.M.G., Li H.Y. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome in adult patients: a systematic review and meta-analysis. Rev. Bras. Ter. Intensive. 2019; 31 (4): 548–554. DOI: 10.5935/0103-507X.20190077.

218. Combes A., Hajage D., Capellier G. et al Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N. Engl. J. Med. 2018; 378 (21): 1965–1975. DOI: 10.1056/NEJMoa1800385.

219. Patroniti N., Bonatti G., Senussi T., Robba C. Mechanical ventilation and respiratory monitoring during extracorporeal membrane oxygenation for respiratory support. Ann. Transl. Med. 2018; 6 (19): 386. DOI: 10.21037/atm.2018.10.11.

220. Ceccato A, Ferrer M, Barbeta E., Torres A. Adjunctive therapies for community-acquired pneumonia. Clin. Chest Med. 2018; 39 (4): 753–764. DOI: 10.1016/j.ccm.2018.07.008.

221. Jiang S., Liu T., Hu Y. et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. Medicine (Baltimore). 2019; 98 (26): e16239. DOI: 10.1097/MD.0000000000016239.

222. Annane D., Bellissant E., Bollaert P.E. et al. Corticosteroids in treatment severe sepsis and septic shock in adults: a systematic review. JAMA. 2009; 301 (22): 2362–2375. DOI: 10.1001/jama.2009.815.

223. Annane D., Sebille V., Bellisant E., Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic schock patients with or without early acute respiratory distress syndrome. Crit. Care Med. 2006; 34 (1): 22–30. DOI: 10.1097/01.CCM.0000194723.78632.62.

224. Annane D., Sebille V., Charpentier C. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288 (7): 862–871. DOI: 10.1001/jama.288.7.862.

225. Wan Y.D., Sun T.W., Liu Z.Q. et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest. 2016; 149 (1): 209–219. DOI: 10.1378/chest.15-1733.

226. Feldman C., Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J. Thorac. Dis. 2016; 8 (3): 162–171. DOI: 10.21037/jtd.2016.02.43.

227. Cronin L., Cook D.J., Carlet J. et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 1995; 23 (8): 1430–1439. DOI: 10.1097/00003246-199508000-00019.

228. Fang F., Zhang Yu., Tang J. et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern. Med. 2019; 179 (2): 213–223. DOI: 10.1001/jamainternmed.2018.5849.

229. Torres A., Sibila O., Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high in ammatory response: a randomized clinical trial. JAMA. 2015; 313 (7): 677–686. DOI: 10.1001/jama.2015.88.

230. Chen L.P., Chen J.H., Chen Y. et al. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. World J. Emerg. Med. 2015; 6 (3): 172–178. DOI: 10.5847/wjem.j.1920-8642.2015.03.002.

231. Siemieniuk R.A., Meade M.O., Alonso-Coello P. et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann. Intern. Med. 2015; 163 (7): 519–528. DOI: 10.7326/m15-0715.

232. Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. Intravenous immunoglobulin for treting sepsis and septic shock. Cochrane Database Syst. Rev. 2002; (1): CD001090. DOI: 10.1002/14651858.CD001090.

233. Haque K.N., Remo C., Bahakim H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin. Exp. Immunol. 1995; 101 (2): 328–333. DOI: 10.1111/j.1365-2249.1995.tb08359.x.

234. Kreymann K.G., de Heer G., Nierhaus A., Kluge S. Use polyclonal immunoglobulin as adjunctive therapy for severe sepsis and septic shock. Crit. Care Med. 2007; 35 (12): 2677–2685. Available at: https://journals.lww.com/ccmjournal/toc/2007/12000

235. Turgeon A. F., Hutton B., Fergusson D.A. et al. Meta-analysis: Intravenous immunoglobulin in crically ill audult patients with sepsis. Ann. Int. Med. 2007; 146 (3): 193–203. DOI: 10.7326/0003-4819-146-3-200702060-00009.

236. Laupland K.B., Kirpatrick A.W., Delaney A. Polyclonal immunoglobulin for treatment severe sepsis and septic shock in crically ill audults: a systematic review and meta-analysis. Crit. Care Med. 2007; 35: 2686–2692. Available at: https://journals.lww.com/ccmjournal/Abstract/2007/12000/Polyclonal_intravenous_immunoglobulin_for_the.2.aspx

237. Bo L., Wang F., Zhu J. et al. Granulocyte-colony stimulating factor(G-CSF) and Granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: meta-analysis. Crit. Care. 2011; 15 (1): R58. DOI: 10.1186/cc10031.

238. Cheng A.C., Stephens D.P., Currie B.J. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst. Rev. 2007; (2): CD004400. DOI: 10.1002/14651858.CD004400.pub3.

239. Meisel C., Schefold J.C., Pschowski R. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 2009; 180 (7): 640–648. DOI: 10.1164/rccm.200903-0363OC.

240. Mismetti P., Laporte-Simitsidis S., Tardy B. et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb. Haemost. 2000; 83 (1): 14–19. Available at: https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0037-1613749

241. Diao W.Q., Shen N., Yu P.X. et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials. Vaccine. 2016; 34 (13): 1496–1503. DOI: 10.1016/j.vaccine.2016.02.023.

242. McLaughlin J., Jiang Q., Isturiz R.E. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin. Infect. Dis. 2018; 67 (10): 1498–1506. DOI: 10.1093/cid/ciy312.

243. Bonten , M.J.M., Huijts S.M., Bolkenbaas M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Eng.l J. Med. 2015; 372 (12): 1114–11125. DOI: 10.1056/NEJMoa1408544.

244. Frenck R.W. Jr, Gurtman A., Rubino J. et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin. Vaccine Immunol. 2012; 19 (8): 1296–1303. DOI: 10.1128/CVI.00176-12.

245. Schwarz T.F., Flamaing J., Rümke H.C. et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. Vaccine. 2011; 29 (32): 5195–5202. DOI: 10.1016/j.vaccine.2011.05.031.

246. Ofori-Anyinam O., Leroux-Roels G, Drame M. et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥ 50years of age: results from a phase III, randomized, non-inferiority trial. Vaccine. 2017; 35 (46): 6321–6328. DOI: 10.1016/j.vaccine.2017.09.012.

247. Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available at: https://www.cdc.gov/vaccines/acip/index.html

248. Козлов Р.С., Авдеев С.Н., Брико Н.И. и др. Вакцинопрофилактика пневмококковых инфекций у взрослых. Клиническая микробиология и антимикробная химиотерапия. 2018; 20 (1): 5–8. Доступно на: https://cmac-journal.ru/publication/2018/1/cmac-2018-t20-n1-p005/cmac-2018-t20-n1-p005.pdf.

249. Методические рекомендации по профилактике заболевания / синдромов. Вакцинопрофилактика пневмококковой инфекции у взрослых. М.; 2019.

250. Falkenhorst G, Remschmidt C., Harder T. et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017; 12 (1): e0169368. DOI: 10.1371/journal.pone.0169368.

251. Restivo V., Costantino C., Bono S. et al. Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies. Hum. Vaccin. Immunother. 2018; 14 (3): 724–735. DOI: 10.1080/21645515.2017.1321722.

252. Приказ Министерства здравоохранения Россиской Федерации от 21.03.14 № 125н «Об утверждении национального календаря профилактических прививок и календаря прививок по эпидемическим показаниям» (дополнения от 04.07.16. Приказ № 370н). Доступно на: https://normativ.kontur.ru/document?moduleId=1&documentId=379483.

253. Министерство здравоохранения Россиской Федерации. Рекомендации по вакцинации беременных женщин. Доступно на: https://www.rosminzdrav.ru/poleznye-resursy/rekomendatsii-po-vaktsinatsii-beremennyh-zhenschin.

254. Постановление Главного государственного санитарного врача Российской Федерации от 25.06.18 г. N 38 г. Москва «О мероприятиях по профилактике гриппа и острых респираторных вирусных инфекций в эпидемическом сезоне 2018–2019 годов». Российская газета. 25.07.18. Доступно на: https://rg.ru/2018/07/25/profilaktika-dok.html.

255. Metlay J.P., Atlas S.J., Borowsky L.H. Singer D.E. Time course of symptom resolution in patients with community-acquired pneumonia. Respir. Med. 1998; 92 (9): 1137–1142. DOI: 10.1016/s0954-6111(98)90408-5.

256. Moussaoui R.E., Opmeer B.C., de Borgie C.A.J.M. et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest. 2006; 130 (4): 1165–1172. DOI: 10.1378/chest.130.4.1165.

257. Wyrwich K.W., Yu H., Sato R., Powers J.H. Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire. Patient Relat Outcome Meas. 2015; 6: 215–223. DOI: 10.2147/PROM.S85779.

258. Cangemi R., Calvieri C., Falcone M. et al. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. Am. J. Cardiol. 2015; 116 (4): 647–651. DOI: 10.1016/j.amjcard.2015.05.028.

259. Pieralli F., Vannucchi V., Nozzoli C. et al. Acute cardiovascular events in patients with community acquired pneumonia: results from the observational prospective FADOI-ICECAP study. BMC Infect. Dis. 2021; 21 (1): 116. DOI: 10.1186/s12879-021-05781-w.

260. Lim W.S., van der Eerden M.M., Laing R. et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58 (5): 377–382. DOI: 10.1136/thorax.58.5.377.

261. Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336 (4): 243–250. DOI: 10.1056/NEJM199701233360402.

262. Фесенко О.В., Синопальников А.И. Современные системы оценки внебольничной пневмонии тяжелого течения: перспективы и ограничения. Клиническая микробиология и антимикробная химиотерапия. 2011; 13 (3): 204–213. Доступно на: https://cmac-journal.ru/publication/2011/3/cmac-2011-t13-n3-p204/cmac-2011-t13-n3-p204.pdf.

263. Руднов В.А., Фесенко А.А., Дрозд А.В. Сравнительный анализ информационной значимости шкал для оценки тяжести состояния больных с внебольничной пневмонией, госпитализированных в ОРИТ. Клиническая микробиология и антимикробная химиотерапия. 2007; 9 (4): 330–336. Доступно на: https://cmac-journal.ru/publication/2007/4/cmac-2007-t09-n4-p330/cmac2007-t09-n4-p330.pdf.

264. Зайцев А.А., Овчинников Ю.В., Кондратьева Т.В. Анализ клинико-диагностических возможностей инструментов оценки тяжести и прогноза внебольничной пневмонии у пациентов молодого возраста из организованных коллективов. Пульмонология. 2014; (5): 67–72. DOI: 10.18093/0869-0189-2014-0-5-67-72.

265. Charles P.G.P., Wolfe R., Whitby M. et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis. 2008; 47 (3): 375–384. DOI: 10.1086/589754.

266. Fukuyama H., Ishida T., Tachibana H. et al. Validation of scoring systems for predicting severe community-acquired pneumonia. Intern. Med. 2011; 50 (18): 1917–1922. DOI: 10.2169/internalmedicine.50.5279.

267. Salih W., Schembri S., Chalmers J.D. Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur. Respir. J. 2014; 43 (3): 842–851. DOI: 10.1183/09031936.00089513.

268. Kuhajda I., Zarogoulidis K., Tsirgogianni K. et al. Lung abscess-etiology, diagnostic and treatment options. Ann. Transl. Med. 2015; 3 (13): 183. DOI: 10.3978/j.issn.2305-5839.2015.07.08.

269. Rome L., Murali G., Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med. Clin. North. Am. 2001; 85 (6): 1511– 1530. DOI: 10.1016/s0025-7125(05)70393-x.

270. Рекомендации МАКМАХ «Определение чувствительности микроорганизмов к антимикробным препаратам (2021)». Доступно на: https://www.antibiotic.ru/minzdrav/category/clinical-recommendations/.

271. Haque N.Z., Zuniga L.C., Peyrani P. et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest. 2010; 138 (6): 1356–1362. DOI: 10.1378/chest.09-2453.


Рецензия

Для цитирования:


Авдеев С.Н., Дехнич А.В., Зайцев А.А., Козлов Р.С., Рачина С.А., Руднов В.А., Синопальников А.И., Тюрин И.Е., Фесенко О.В., Чучалин А.Г. Внебольничная пневмония: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):295-355. https://doi.org/10.18093/0869-0189-2022-32-3-295-355

For citation:


Avdeev S.N., Dekhnich A.V., Zaytsev A.A., Kozlov R.S., Rachina S.A., Rudnov V.A., Sinopal’nikov A.I., Tyurin I.E., Fesenko O.V., Chuchalin A.G. Federal guidelines on diagnosis and treatment of community-acquired pneumonia. PULMONOLOGIYA. 2022;32(3):295-355. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-3-295-355

Просмотров: 172


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)